Information Provided By:
Fly News Breaks for August 4, 2016
INSY
Aug 4, 2016 | 07:25 EDT
Jefferies analyst David Steinberg raised his price target for Insys Therapeutics to $22 saying Subsys scripts appear to have stabilized following the company's in-line Q2 results. The most important element of earnings call was the comment that "we're very optimistic that it [settlement with the DOJ] could happen by end of the year," Steinberg tells investors in a research note. The analyst views the Department of Justice investigation as "by far the most important overhang to the story." He keeps a Buy rating on Insys.
News For INSY From the Last 2 Days
There are no results for your query INSY